Alcon Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ALC | 7780.T | HYB.F | 300677.SZ | EL.PA | 7743.T | |
|---|---|---|---|---|---|---|
| Market cap | 37.37B | 140.12B | 44.46B | 29.65B | 87.27B | 23.76B |
| P/E (TTM) | 58.6 | 19.7 | 29.1 | 100.6 | 35.6 | 21.8 |
| Forward P/E | 19.6 | 18.4 | 32.5 | 19.2 | 24.0 | 17.0 |
| Price/book | 1.7 | 1.5 | 7.8 | 1.6 | 2.2 | 1.2 |
| Dividend yield | 0.46% | 1.58% | 1.31% | 0.44% | 2.12% | 1.91% |
| 1-year change | −2.65% | +44.25% | −1.81% | +15.58% | −41.75% | +39.18% |
| Today | +6.83% | +6.61% | −2.41% | +0.09% | +0.69% | 0.00% |
The closest companies by business and industry (Medical Instruments & Supplies). Prices may be delayed up to 20 min.
Latest news
All ALC news ›Vitreous Tamponade Market Led by Alcon, Bausch + Lomb and Fluoron Drive Growth Through Heavy Silicone Oils and Short-Acting Gas Tamponades | SNS Insider
Vitreous Tamponade Market Growth Gains Pace as Vitreoretinal Surgery Volumes Rise According to a recent study by SNS Insider the global Vitreous Tamponade Market was valued at USD 89 85 million in 2025 and is projected to reach USD 161 ...…
Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback
Shares of LENSAR, Inc. (NSR) slumped 24% after hours on Monday after the company terminated its merger agreement with eye care company Alcon Research, LLC (ALC). The commercial-stage medical device company Lensar said on Monday that the…
Bernstein: Alcon a 'Top Long-term Compounder' Amid 'Transitory' Near-term Pressures
Bernstein sees Alcon as a top long-term compounder, saying it views recent market pressure in the Swiss eye care company's intraocular lens, or IOL, segment as transitory. Alcon remains our... Published on 09/24/2026 at 05:25 am EDT Modest…
Alcon Acquires Neurotech Pharmaceuticals For $550 Million To Add FDA-Approved ENCELTO Retinal Therapy
Alcon has acquired Neurotech Pharmaceuticals for $550 million, expanding its retina portfolio with ENCELTO, the first and only U.S. FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2, or MacTel. Neurotech…
Alcon: Keeping An Eye Out Here Amid Sales And Margin Momentum
Alcon's stock has reset, improving risk-reward. See how sales growth, margin expansion, and innovation support its mid-term outlook. - Alcon's shares have corrected to $70, compressing the earnings multiple from 25x to 20x and improving…
Alcon bolsters retina portfolio with $550m Neurotech acquisition
Alcon will add the first and only FDA approved treatment for macular telangiectasia type 2 to its retina portfolio. MacTel is a rare, progressive neurodegenerative disease that causes irreversible loss of central vision, and until Encelto…
Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition
Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a majority stake in Aurion Biotech, a startup developing a…
Alcon acquires Neurotech and ENCELTO, the only FDA-approved treatment for MacTel Type 2
Alcon announced it has acquired Neurotech Pharmaceuticals, Inc., a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases. This acquisition expands Alcon's retina portfolio with ENCELTO…
Alcon acquires Neurotech, MacTel therapy Encelto
Alcon, Inc. has purchased Neurotech Pharmaceuticals, Inc., developer of the first and only FDA-approved treatment for Macular Telangiectasia Type 2 (MacTel). Alcon shared two details surrounding the transaction: Headquartered in…
Alcon Pays $550 Million for Neurotech and Its MacTel Cell Therapy
FDA approved revakinagene taroretcel under a biologics license application in March 2025,2 after granting it priority review and orphan drug designation.1 In NTMT-03-A, ellipsoid zone loss was 0.075 mm2 in treated eyes vs 0.166 mm2 in…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com3
- glance.eyesoneyecare.com2
- stocktitan.net2
- alcon.com1
- biopharminternational.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 26 articles, not a forecast.